Umbilical cord derived mesenchymal stem cell therapy (Restem)

N/A

Report date: 2025/12/11 17:52:57

Base Information

Drug NameUmbilical cord derived mesenchymal stem cell therapy (Restem)
Drug Alias NameRestem-LUmbilical cord lining stem cells (ULSC)Umbilical Cord Lining Stem Cell Therapy
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, AdultDermatomyositis +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesRestem LLC
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of FloridaRestem LLC
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, AdultDermatomyositis +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A